Health Risk Factor Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Risk Factor Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

CHU Jean Minjoz, Besancon

Review details clinical potential of stem cell sources for cardiac cell therapy

According to a report from France, "Myocardial infarction is the leading cause of heart failure in developed countries. The therapeutic measures of today are usually not sufficient to prevent left ventricular remodeling as they fall short of actual replacement of necrotic cardiac myocytes."

S. Davani and colleagues of CHU Jean Minjoz in Besancon continued, "However, current insights into stem cell plasticity have opened up new perspectives for regenerating the infarcted heart. Recently, a wide range of stem/progenitor cell types have been used for cardiac cell therapy (CCT), including embryonic or fetal stem cells,...

• View Other Issues of Health Risk Factor Week
  
• View Other NewsRx Publications